TY - JOUR
T1 - Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups
AU - EPAD Study Group
AU - Investigators from ACT
AU - Investigators from ROS
AU - Investigators from MAP
AU - Investigators from ADNI
AU - Investigators from the University of Pittsburgh ADRC
AU - Mukherjee, Shubhabrata
AU - Mez, Jesse
AU - Trittschuh, Emily H.
AU - Saykin, Andrew J.
AU - Gibbons, Laura E.
AU - Fardo, David W.
AU - Wessels, Madeline
AU - Bauman, Julianna
AU - Moore, Mackenzie
AU - Choi, Seo Eun
AU - Gross, Alden L.
AU - Rich, Joanne
AU - Louden, Diana K.N.
AU - Sanders, R. Elizabeth
AU - Grabowski, Thomas J.
AU - Bird, Thomas D.
AU - McCurry, Susan M.
AU - Snitz, Beth E.
AU - Kamboh, M. Ilyas
AU - Lopez, Oscar L.
AU - De Jager, Philip L.
AU - Bennett, David A.
AU - Keene, C. Dirk
AU - Larson, Eric B.
AU - Crane, Paul K.
N1 - Publisher Copyright:
© 2018, The Author(s).
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Categorizing people with late-onset Alzheimer’s disease into biologically coherent subgroups is important for personalized medicine. We evaluated data from five studies (total n = 4050, of whom 2431 had genome-wide single-nucleotide polymorphism (SNP) data). We assigned people to cognitively defined subgroups on the basis of relative performance in memory, executive functioning, visuospatial functioning, and language at the time of Alzheimer’s disease diagnosis. We compared genotype frequencies for each subgroup to those from cognitively normal elderly controls. We focused on APOE and on SNPs with p < 10−5 and odds ratios more extreme than those previously reported for Alzheimer’s disease (<0.77 or >1.30). There was substantial variation across studies in the proportions of people in each subgroup. In each study, higher proportions of people with isolated substantial relative memory impairment had ≥1 APOE ε4 allele than any other subgroup (overall p = 1.5 × 10−27). Across subgroups, there were 33 novel suggestive loci across the genome with p < 10−5 and an extreme OR compared to controls, of which none had statistical evidence of heterogeneity and 30 had ORs in the same direction across all datasets. These data support the biological coherence of cognitively defined subgroups and nominate novel genetic loci.
AB - Categorizing people with late-onset Alzheimer’s disease into biologically coherent subgroups is important for personalized medicine. We evaluated data from five studies (total n = 4050, of whom 2431 had genome-wide single-nucleotide polymorphism (SNP) data). We assigned people to cognitively defined subgroups on the basis of relative performance in memory, executive functioning, visuospatial functioning, and language at the time of Alzheimer’s disease diagnosis. We compared genotype frequencies for each subgroup to those from cognitively normal elderly controls. We focused on APOE and on SNPs with p < 10−5 and odds ratios more extreme than those previously reported for Alzheimer’s disease (<0.77 or >1.30). There was substantial variation across studies in the proportions of people in each subgroup. In each study, higher proportions of people with isolated substantial relative memory impairment had ≥1 APOE ε4 allele than any other subgroup (overall p = 1.5 × 10−27). Across subgroups, there were 33 novel suggestive loci across the genome with p < 10−5 and an extreme OR compared to controls, of which none had statistical evidence of heterogeneity and 30 had ORs in the same direction across all datasets. These data support the biological coherence of cognitively defined subgroups and nominate novel genetic loci.
UR - http://www.scopus.com/inward/record.url?scp=85058024274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058024274&partnerID=8YFLogxK
U2 - 10.1038/s41380-018-0298-8
DO - 10.1038/s41380-018-0298-8
M3 - Article
C2 - 30514930
AN - SCOPUS:85058024274
SN - 1359-4184
VL - 25
SP - 2942
EP - 2951
JO - Molecular psychiatry
JF - Molecular psychiatry
IS - 11
ER -